OS Therapies Incorporated (OSTX) 銘柄情報

Form 8-K - Current report

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

OS Therapies to Present at The Spartan Capital Investor Conference

OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief...

Form 8-K - Current report

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and...

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness...

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness...